Stay updated with breaking news from Budd Haeberlein. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Aducanumab, lecanemab, and donanemab are novel monoclonal antibodies designed to slow disease progression and hopefully have a positive impact in the field of Alzheimer disease management.
Pharmacists play a key role in the management of modern monoclonal antibody treatments for Alzheimer disease.
Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers Appointment of... | May 9, 2023
Medically reviewed by Dr. Ari Magill First described by Alois Alzheimer in 1906, Alzheimer's disease (AD) is a ...
Confirmatory trial’s completion is expected in an accelerated timeline of four years with patient screening to start in MayMultiple strategies in place to enroll patients that are representative... | March 30, 2022